{"id":534345,"date":"2021-09-03T09:03:15","date_gmt":"2021-09-03T13:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/"},"modified":"2021-09-03T09:03:15","modified_gmt":"2021-09-03T13:03:15","slug":"royalty-pharma-to-present-at-upcoming-investor-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/","title":{"rendered":"Royalty Pharma to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Sept.  03, 2021  (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:<\/p>\n<ul type=\"disc\">\n<li>Citi\u2019s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT<\/li>\n<li>Morgan Stanley\u2019s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 11:00 a.m. EDT<\/li>\n<\/ul>\n<p>The webcasts will be accessible from Royalty Pharma\u2019s \u201cEvents\u201d page at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DLHZ-kHscm-tAwlF6nxcoZzs5UBauUQOsL7H-fqDmB6Tw6uHLNC8diVv0nrmqkiwPXGm0zAZG4UB9YP06GlFZ9FVHELZIUHnofBBIGoiyV6HqSH2GtDq8FKdTV_gqvkJgKOaMVZJRCnGiFPtb79lqqvziPp8BfqTSZl8p_zT9NuR-szFJbo3Am0s4m-8iC09KTyNR_l9zogwtEt6XxAj2Q==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.royaltypharma.com\/investors\/news-and-events\/events<\/a>. Webcasts will also be archived for a minimum of thirty days.<\/p>\n<p align=\"justify\">\n        <strong>About Royalty Pharma plc <\/strong>\n      <\/p>\n<p>Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry\u2019s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly &#8211; directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma\u2019s current portfolio includes royalties on more than 45 commercial products, including AbbVie and Johnson &amp; Johnson\u2019s Imbruvica, Astellas\u2019 and Pfizer\u2019s Xtandi, Biogen\u2019s Tysabri, Johnson &amp; Johnson\u2019s Tremfya, Gilead\u2019s Trodelvy, Merck\u2019s Januvia, Novartis\u2019 Promacta, Vertex\u2019s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=29wMocS8yQVlJ9Vvy_IU-M5Wh0I67K1V2f91RugG9XOOhK69dF686XGZxmrMGcqGQBJnoIy_UBfsfoEFS30qlV3At_KejorMvMpSjExpmsY=\" rel=\"nofollow noopener\" target=\"_blank\">www.royaltypharma.com<\/a>.<\/p>\n<p>\n        <strong>Royalty Pharma Investor Relations and Communications<\/strong>\n      <\/p>\n<p align=\"justify\">+1 (212) 883-6772<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HR4VhzflQKvpeo3p6eG-FKqrVS7EkL8ONhA2H4XVQ6ZEkW6rAyrRjmjvxInuQXPJBZJTII8Ryq6pWdgcDKSCsAT4GBa2eDwy_D2Llj1piWo=\" rel=\"nofollow noopener\" target=\"_blank\">ir@royaltypharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODk3NTk5ZWMtMTVhNC00MTlmLThiYWMtNDI3ZThlZjczOTU3LTEyMDcxMTA=\/tiny\/RP-Management-LLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi\u2019s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT Morgan Stanley\u2019s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 11:00 a.m. EDT The webcasts will be accessible from Royalty Pharma\u2019s \u201cEvents\u201d page at https:\/\/www.royaltypharma.com\/investors\/news-and-events\/events. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Royalty Pharma to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534345","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Royalty Pharma to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Royalty Pharma to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi\u2019s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT Morgan Stanley\u2019s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 11:00 a.m. EDT The webcasts will be accessible from Royalty Pharma\u2019s \u201cEvents\u201d page at https:\/\/www.royaltypharma.com\/investors\/news-and-events\/events. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- &hellip; Continue reading &quot;Royalty Pharma to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-03T13:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Royalty Pharma to Present at Upcoming Investor Conferences\",\"datePublished\":\"2021-09-03T13:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/\",\"name\":\"Royalty Pharma to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=\",\"datePublished\":\"2021-09-03T13:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Royalty Pharma to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Royalty Pharma to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Royalty Pharma to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi\u2019s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT Morgan Stanley\u2019s 19th Annual Global Healthcare Conference on Tuesday, September 14 at 11:00 a.m. EDT The webcasts will be accessible from Royalty Pharma\u2019s \u201cEvents\u201d page at https:\/\/www.royaltypharma.com\/investors\/news-and-events\/events. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small- &hellip; Continue reading \"Royalty Pharma to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-03T13:03:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Royalty Pharma to Present at Upcoming Investor Conferences","datePublished":"2021-09-03T13:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/","name":"Royalty Pharma to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=","datePublished":"2021-09-03T13:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDAzNCM0Mzg4NTI3IzIxOTU1NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/royalty-pharma-to-present-at-upcoming-investor-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Royalty Pharma to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534345"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}